Member Info for Timster

I agree with your last post Sirius we are in the "summer" delivery timescale phase, summer ends 22nd September so they have head room.
It seems impossible for big Al to give firm time scales as they are in uncharted territory condensing a usual 1 to 2 year process into a few months.
Hell of a lot going on and some very interesting weeks ahead... GLA....

Agreed egtp if these two covid tests get approval and go to market it will be a momentous achievement for avacta and proof that the affirmer tech can be applied in the real world.
The "astronomical " income that can come from that alone will propel avacta into the big time. But it also opens the door for an affirmer revolution and massive interest from large pharmaceutical companies wanting a piece of the pie.
Exciting times ahead...

Great post again monkshood.

What a success will do is prove the viability of affirmers across different applications. We know they work in lfd too with some optimisation required.

Sir Al has talked about different types of tests a few times so we could well have that to add to the list of upcoming possible news items

Bloody deramper! ;)

You not been out in Cardiff then :)

So still a need for a rapid test if that's what your getting at.
If a vaccine does actually work it's still a long way off

Made a right mess of my last thread so thought I'd try again, shame you can't delete stuff

Bit of a crap week share price wise but as the best in the business say "be rude not to have topped up"
What do we know for sure, not in a fantasy world now!!
1. It's the START of summer, not the middle or the end.

2. On the 9th of June avacta told us:
The next step in the development of the final product to run on the installed base of mass spectrometers in clinical laboratories around the world is to evaluate and optimise the BAMS assay using patient samples at laboratory sites in the UK and US which will be done imminently before moving to manufacturing, clinical validation to quantify the sensitivity and specificity and CE/FDA approval for professional use in the summer.

3.Cytiva have produced a lateral flow device and:
data show that the test strips detect the spike protein in model samples at concentrations within the clinical range found in saliva of patients with COVID-19. Work continues now to refine the test strip design, optimise its performance and get the best detection limit possible in order to generate the highest sensitivity in the final rapid test product.

Following the optimisation of the lateral flow test by Cytiva the design will then be transferred to manufacturing partners in the UK that are currently being put in place by Avacta. The Company is working with these manufacturers to compress the normal manufacturing, clinical validation and regulatory timelines in order to bring a product to market as quickly as possible.

So sit back and relax, summer is here

This is how this thread reads in my head now:
Voice of screaming drunk woman -" leave it leave it he's not worth it PL75"
PL75- taking white vest off, Stella can thrown to the floor "gonna Mark you up wiv my sovs ophi"

Bit of a crap week share price wise but as the best in the business say "be rude not to have topped up"
What do we know for sure, not in a fantasy world now!!
1. It's the START of summer, not the middle or the end.

2. On the 9th of June avacta told us:
The next step in the development of the final product to run on the installed base of mass spectrometers in clinical laboratories around the world is to evaluate and optimise the BAMS assay using patient samples at laboratory sites in the UK and US which will be done imminently before moving to manufacturing, clinical validation to quantify the sensitivity and specificity and CE/FDA approval for professional use in the summer.

3.Cytiva have produced a lateral flow device and:
data show that the test strips detect the spike protein in model samples at concentrations within the clinical range found in saliva of patients with COVID-19. Work continues now to refine the test strip design, optimise its performance and get the best detection limit possible in order to generate the highest sensitivity in the final rapid test product.

Following the optimisation of the lateral flow test by Cytiva the design will then be transferred to manufacturing partners in the UK that are currently being put in place by Avacta. The Company is working with these manufacturers to compress the normal manufacturing, clinical validation and regulatory timelines in order to bring a product to market as quickly as possible.

So sit back and relax

****** hit the post too early
3. Cytiva have produced a lateral flow device and:
data show that the test strips detect the spike protein in model samples at concentrations within the clinical range found in saliva of patients with COVID-19. Work continues now to refine the test strip design, optimise its performance and get the best detection limit possible in order to generate the highest sensitivity in the final rapid test product.



Following the optimisation of the lateral flow test by Cytiva the design will then be transferred to manufacturing partners in the UK that are currently being put in place by Avacta. The Company is working with these manufacturers to compress the normal manufacturing, clinical validation and regulatory timelines in order to bring a product to market as quickly as possible.

So sit back and relax

Bit of a crap week share price wise but as the best in the business say "be rude not to have topped up"
What do we know for sure, not in a fantasy world now!!
1. It's the START of summer, not the middle or the end.

2. On the 9th of June avacta told us:
The next step in the development of the final product to run on the installed base of mass spectrometers in clinical laboratories around the world is to evaluate and optimise the BAMS assay using patient samples at laboratory sites in the UK and US which will be done imminently before moving to manufacturing, clinical validation to quantify the sensitivity and specificity and CE/FDA approval for professional use in the summer.

3.

bump, how about stop responding !! by doing so you are getting a negative thread to the top of the board

bump, use the FACTS Luke, the FACTS will always be with you ...

just checked back in! the trolls in charge by the looks desperately talking it down to 1.20 I'm guessing

Nothing else to say without new news so I'll be off to do some work.

Worth re-posting this link Avacta have very usefully put all their FACTS about Covid related work in one place:
https://avacta.com/diagnostics/covid-19/

Big Al keeps stating that this process is normally a year to two years in the making so I don't think there is a lack of clarity. They are in uncharted territory trying to squeeze tried and tested 2 year processes into a few months.
fro what we are being told I'm confident it will be done, we just need to accept the vast challenges that they are working to overcome.

so what!

thought about trading the usual drop this morning and bottled it. There is so much news to come it really makes no difference what the intra day price does (to a longer term holder, who's ****e at trading)). If we get positive news on either of the current tests or on blocking therapeutics then the SP will be way higher and worth commenting on.

Sounds promising, like something out of star trek;)

Still won't be available till next year if it works

I didn't, is that what trump was on about?